{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-21-000141","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2021-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.906018+00:00","generated_at":"2026-06-29T23:13:43.667597+00:00","sec_items":["2.01","3.02"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veracyte completes €260M acquisition of HalioDx in cash and stock","bullets":["Total consideration €260M: ~€147M cash + ~€113M in Veracyte common stock.","Acquisition of HalioDx, a French immuno-oncology diagnostics company.","Closing on August 2, 2021, as previously announced June 1 and July 13.","Stock consideration issued as unregistered securities under Item 3.02."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-21-000141","json":"https://secwatch.observer/filing/0001384101-21-000141.json","markdown":"https://secwatch.observer/filing/0001384101-21-000141.md","text":"https://secwatch.observer/filing/0001384101-21-000141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410121000141/0001384101-21-000141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410121000141/vcyt-20210802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T23:13:43.667597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}